CTI Clinical Trial and Consulting Services Announces the Formation of CTI Clinical Trial and Consulting Services Spain SL
CTI Clinical Trial and Consulting Services
(CTI) announces the formation of CTI Clinical Trial and Consulting Services Spain, SL. This new geographic office location will allow CTI to better meet the needs of its sponsors throughout Europe. Spain has always been a key contributor to the clinical research field and, in recent years, has seen an increase in the number of clinical trials conducted in the country. The new CTI office will be located in Madrid.
“The pharmaceutical and biotechnology industries continue to be very interested in conducting clinical research in Spain due to the quality of the clinical sites, the investigators, and the data they provide,” states Timothy J. Schroeder, CTI President and CEO. “Our therapeutic areas mesh well with the type of research conducted in Spain and our new office will help us better meet the needs of our sponsors.” The CTI Madrid Office complements its clinical trial services offering in Western Europe. CTI’s EU Team, with headquarters in Ulm, Germany, has managed clinical trials in multiple EU countries for many years.
CTI has been working for more than a decade in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.
